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Background
Exotic tropical fruits and plants are highly consumed in
Brazil and due to globalization these products are being
exported worldwide. We have recently described the
first manioc allergen Man e 5 that cross-reacts with Hev
b 5 from latex. There are more than 70 products made
up manioc starch such as drugs, soaps and fabrics and
manioc allergic patients present from mild to severe
reactions.
Methods
Five patients with manioc allergy confirmed by skin
prick test (SPT) and oral challenge were selected. These
patients were evaluated through SPT and Immunocap
to latex, ELISA and ISAC inhibition with manioc extract
and rMan e 5. Among these patients we selected a Bra-
zilian woman that lives in North region where manioc is
consumed in a daily diet for an oral immunotherapy
(OIT) protocol. The patient is a hairdresser, 48 years
old, IgE mediated latex allergy. Six years ago she started
to have episodes of anaphylaxis to manioc, but more
recently she began to present allergic manifestations
after inhalatory exposition to manioc starch. Patient was
then submitted to OIT with manioc starch solubilized
in 10mg/mL. Immunotherapy was divided in two parts:
induction and maintenance. In the first phase dose was
weekly increased starting with 0.1mL of a 10mg/mL
until reaching an amount of 10g of manioc starch. At
this point the patient was submitted to oral provocation
with 100g of manioc. For maintenance it was indicated
daily ingestion of foods prepared with manioc. Clinical
evaluation, skin tests and IgE levels after 1 and 6 months
were performed.
Results
All five patients had anaphylaxis to manioc with IgE sensi-
tization to manioc and latex. Inhibition assays showed that
rMan e 5 is not the only manioc allergen and that there is
a molecule in manioc cross-reacting with Hev b 6. After
OIT patient presented a decrease of the wheal in SPT (10
to 4mm) and also in IgE levels to latex. Oral provocation
was negative. Reactions during treatment were mild
(abdominal pain and oral itching) and solved sponta-
neously or using antihistaminic. After two years under
maintenance patient keeps asymptomatic eating manioc
without restrictions.
Conclusions
There are at least two manioc allergens cross-reacting with
latex. OIT was proved to be safe and efficient in this case
allowing free ingestion of manioc leading us to conduct
the protocol with other patients. Levels of latex IgE also
decreased after treatment. Knowledge of single allergens is
important for diagnosis and also to monitor therapeutic
success.
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